Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
The American Journal of Cardiology
|
February 24, 2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)
Matti J Tikkanen, Ingar Holme, Nilo B Cater, et al.
The American Journal of Cardiology
|
July 21, 2010
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Terje R Pedersen, Nilo B Cater, Ole Faergeman, et al.
Circulation
|
July 1, 2004
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum
Sidney C Smith, Rod Jackson, Thomas A Pearson, et al.
JAMA
|
November 17, 2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
Terje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
Journal of the American College of Cardiology
|
January 20, 2010
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial
Matti J Tikkanen, Michael Szarek, Rana Fayyad, et al.
BMC Medical Genetics
|
February 11, 2005
Familial hypercholesterolemia in St-Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia
Faina M Zakharova, Dorte Damgaard, Michail Y Mandelshtam, et al.
Atherosclerosis. Supplements
|
November 9, 2004
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998
Terje R Pedersen, Anders G Olsson, Ole Faergeman, et al.
The American Journal of Cardiology
|
August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease
Ole Faergeman, Ingar Holme, Rana Fayyad, et al.
Journal of the American College of Cardiology
|
February 12, 2008
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies
Wim A van der Steeg, Ingar Holme, S Matthijs Boekholdt, et al.
Atherosclerosis
|
December 23, 2003
European guidelines on cardiovascular disease and prevention in clinical practice
Guy De Backer, Ettore Ambrosioni, Knut Borch-Johnsen, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
The American Journal of Cardiology
|
February 24, 2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)
Matti J Tikkanen, Ingar Holme, Nilo B Cater, et al.
The American Journal of Cardiology
|
July 21, 2010
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Terje R Pedersen, Nilo B Cater, Ole Faergeman, et al.
Circulation
|
July 1, 2004
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum
Sidney C Smith, Rod Jackson, Thomas A Pearson, et al.
JAMA
|
November 17, 2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
Terje R Pedersen, Ole Faergeman, John J P Kastelein, et al.
Journal of the American College of Cardiology
|
January 20, 2010
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial
Matti J Tikkanen, Michael Szarek, Rana Fayyad, et al.
BMC Medical Genetics
|
February 11, 2005
Familial hypercholesterolemia in St-Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia
Faina M Zakharova, Dorte Damgaard, Michail Y Mandelshtam, et al.
Atherosclerosis. Supplements
|
November 9, 2004
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998
Terje R Pedersen, Anders G Olsson, Ole Faergeman, et al.
The American Journal of Cardiology
|
August 8, 2009
Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease
Ole Faergeman, Ingar Holme, Rana Fayyad, et al.
Journal of the American College of Cardiology
|
February 12, 2008
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies
Wim A van der Steeg, Ingar Holme, S Matthijs Boekholdt, et al.
Atherosclerosis
|
December 23, 2003
European guidelines on cardiovascular disease and prevention in clinical practice
Guy De Backer, Ettore Ambrosioni, Knut Borch-Johnsen, et al.
Page
of 6